Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 18, Issue 7, Pages E248-E250Publisher
ELSEVIER SCI LTD
DOI: 10.1111/j.1469-0691.2012.03890.x
Keywords
Amphotericin B; Aspergillus; breakpoints; EUCAST Technical Note; itraconazole; posaconazole; susceptibility testing
Categories
Funding
- National Institute of Health
- Astellas
- Gilead
- MSD
- Pfizer
- Astellas Pharma
- bioMerieux
- Gilead Sciences
- Schering Plough
- Soria Melguizo SA
- Ferrer International
- EU
- ALBAN
- Spanish Agency for International Cooperation
- Spanish Ministry of Culture and Education
- Spanish Health Research Fund
- Instituto de Salud Carlos III
- Ramon Areces Foundation
- Mutua Madrilena Foundation
- Merck
- Merck Vectura
- F2G
Ask authors/readers for more resources
Clin Microbiol Infect 2012; 18: E248E250 Abstract The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for amphotericin B, itraconazole and posaconazole for Aspergillus species. This Technical Note is based on the EUCAST amphotericin B, itraconazole and posaconazole rationale documents (available on the EUCAST website: ). The amphotericin B and itraconazole breakpoints are based on epidemiological cut-off values and clinical experience. The posaconazole breakpoints are also based on pharmacokinetic and pharmacodynamic data. Breakpoints will be reviewed regularly or when new data emerge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
